2023
|
1 |
Tang CY (唐振育), Hang JF, Hung YP (洪逸平), Chiu NC, Lai JI (賴峻毅), Chen MH (陳明晃), Liu CY (劉峻宇), Yang MH (楊慕華), Chao Y (趙毅), Chang PM* (張牧新). A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years |
|
2 |
Lee TL, Chen TH (陳天華), Kuo YJ, Lan HY, Yang MH* (楊慕華), Chu PY. Tumor-associated tissue eosinophilia promotes angiogenesis and metastasis in head and neck squamous cell carcinoma |
|
3 |
Chung SY, Chang YC, Hsu DS, Hung YC, Lu ML, Hung YP (洪逸平), Chiang NJ (姜乃榕), Yeh CN, Hsiao M, Soong J, Su Y, Chen MH* (陳明晃). A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer |
|
4 |
Chen MC, Su HY, Su YH, Huang KH, Fang WL, Lin CW, Chen MH (陳明晃), Chao Y (趙毅), Lo SS, Fen-Yau Li A, Wu CW. The clinicopathological and genetic d(IFferences among gastric cancer patients with no recurrence, early recurrence, and late recurrence after curative surgery |
|
5 |
Rau KM, Shun SC, Hung SH, Chou HL, Ho CL, Chao TC (趙大中), Liu CY (劉峻宇), Lien CT, Hong MY, Wu CJ, Tsai LY,2023 Jane SW, Hsieh RK. Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment |
|
6 |
Wu WC (吳紋綺), Chen MH* (陳明晃). Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib |
|
7 |
Chiang NJ (姜乃榕), Chen LT. Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning |
|
8 |
Su YY, Chiang NJ (姜乃榕), Chang JS, Wang YW, Shen BN, Li YJ, Hwang DY, Shan YS, Chen LT. The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan |
|
9 |
Wu WC (吳紋綺), Huang CC, Tsai YF, Lin YS, Feng CJ, Chen YJ, Lai JI (賴峻毅), Chao TC (趙大中), Liu CY* (劉峻宇), Tseng LM. The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis |
|
10 |
Su YY, Chiang NJ (姜乃榕), Yang YH, Yen CJ, Bai LY, Chiu CF, Chuang SC, Yang SH, Chou WC, Chen JS, Chiu TJ, Chen YY, Chan DC, Peng CM, Chiu SC, Li CP, Shan YS, Chen LT. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer |
|
11 |
Kung CY, Fang WL, Hung YP (洪逸平), Huang KH, Chen MH (陳明晃), Chao Y (趙毅), Lin SC, Li AF, Lo SS, Wu CW. Comparison of the mutation patterns between tumor tissue and cell-free DNA in stage IV gastric cancer |
|
12 |
Merle P, Kudo M, Edeline J, Bouattour M, Cheng AL, Chan SL, Yau T, Garrido M, Knox J, Daniele B, Breder V, Lim HY, Ogasawara S, Cattan S, Chao Y (趙毅), Siegel AB,2023 Martinez-Forero I, Wei Z, Liu CC, Finn RS. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial |
|
13 |
Chen MC, Su HY, Su YH, Huang KH, Fang WL, Lin CW, Chen MH (陳明晃), Chao Y (趙毅), Lo SS, FenYau Li A, Wu CW. Reply to “Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?” |
|
14 |
Chueh CH, Tsai YW, Chen ZR, Shiu MN, Wen YW, Chiang NJ* (姜乃榕). Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy |
|
15 |
Shao YY, Ho CL, Chang CS, Chang CL, Lee JK, Lin HJ, Hsiao HH, Chao TC (趙大中), Lin CY, Liaw CC. Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants |
|
16 |
Lin TY, Lee TL, Hsu YB, Tai SK, Wang LW, Yang MH (楊慕華), Chu PY. Survival analyses of d(IFferent treatment modalities and clinical stage for hypopharyngeal carcinoma |
|
17 |
Satake H, Lee KW, Chung HC, Lee J, Yamaguchi K, Chen JS, Yoshikawa T, Amagai K, Yeh KH, Goto M, Chao Y (趙毅), Lam KO, Han SR, Shiratori S, Shah S, Shitara K. Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal2023 Junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062 |
|
18 |
Pan LH, Yen CC (顏厥全), Huang CJ, Ng XN, Lin LY. Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience |
|
19 |
Yang YF, Tsai KW, Chang PM (張牧新), Chang YC. Editorial: Metabolism-based omics integrations, biosensors, and molecular mechanisms in human cancers |
|
20 |
Zheng ZR, Ku HY, Chen KC, Chiang CJ, Wang CL, Chen CY, Tsai CM (蔡俊明), Huang MS, Yu CJ, Chen JS, Chou TY, Lee WC, Wang CC, Liu TW, Hsia JY, Chang GC. Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naive ALK-positive advanced lung adenocarcinoma |
|
21 |
Chen MC, Su HY, Su YH, Huang KH, Fang WL, Lin CW, Chen MH (陳明晃), Chao Y (趙毅), Lo SS, Li AF, Wu CW. Reply to "Can one outcome be used to predict the other outcome?" |
|
22 |
Chen TH (陳天華), Chen MH (陳明晃), Hung YP (洪逸平), Chiang NJ (姜乃榕), Huang KH, Lin YH, Lin RW, Chao Y (趙毅), Li AF, Yu HY, Hwang HE, Yeh YC, Wang YC, Fang WL. Elevated PD-L1 Expression and Microsatellite Instability in Elderly Patients With Gastric Cancer |
|
23 |
Chiu YN, Hsu CY, Lien PJ, Chao TC (趙大中), Liu CY (劉峻宇), Lin YS, Wang YL, Tsai YF, Tseng LM. Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy |
|
24 |
Chen SC* (陳三奇). Challenges in translating clinical guidelines into real-l(IFe practice for management of hepatocellular carcinoma in Taiwan |
|
25 |
Chung CH, Lin CY, Chen CY, Hsueh CW, Chang YW, Wang CC, Chu PY, Tai SK, Yang MH* (楊慕華). Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer |
|
26 |
Wang SF, Lin YS, Yeh WY, Chang YL, Chiang CE, Chen CH, Tseng LM, Lee HC, Liu CY (劉峻宇), Cheng HM. The Clinical Benefits of Antiresorptive Agents in Primary Breast Cancer Patients Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis |
|
27 |
Mienda BS, Cheng C-T, Lai J-M, Chang PM-H (張牧新), Hong Y-R, Huang C-YF, Wang F-S. Ident(IFying essential genes in genome-scale metabolic models of consensus molecular subtypes of colorectal cancer |
|
28 |
Pan YR, Wu CE,2023 Jung SM, Huang SC, Lin SH, Chou WC, Chang YC, Chen MH (陳明晃), Hung TH, Yu AL, Huang WK, Yeh CN. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation |
|
29 |
Su SP, Lee YC, Lin SL, Li YX, Lin MY, Chan YH, Lee YJ, Yang MH (楊慕華), Chiang HK. Realization of NIR-II 3D whole-body contour and tumor blood vessels imaging in small animals using rotational stereo vision technique |
|
30 |
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM (蔡俊明), Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations |
|
31 |
Wu CH, Lai CL, Teng CJ, Fang WL, Huang KH, Fen-Yau Li A, Yu HY, Chiang NJ (姜乃榕), Chao Y (趙毅), Hung YP (洪逸平), Chen MH* (陳明晃). Immunoprofile of adenosquamous carcinoma in gastric cancer |
|
32 |
Su YY, Chao YJ, Wang CJ, Liao TK, Su PJ, Huang CJ, Chiang NJ (姜乃榕), Yu YT, Tsai HM, Chen LT, Shan YS. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study |
|
33 |
Liu YW, Lee JY, Wang YK, Chen YH, Fang PT, Chou SH, Chen MH (陳明晃), Bai LY, Yen CJ, Wu MT, Wu IC. Comparison of therapeutic outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A prospective observational cohort study |
|
34 |
Lin ZH, Yeh H, Lo HC, Hua WJ, Ni MY, Wang LK, Chang TT, Yang MH (楊慕華), Lin TY. GMI, a fungal immunomodulatory protein, ameliorates SARS-CoV-2 envelope protein-induced inflammation in macrophages via inhibition of MAPK pathway |
|
35 |
Fu CC, Wei CY, Chu CJ, Lee PC, Huo TI, Huang YH, Chao Y (趙毅), Hou MC, Wu JC, Su CW. The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels |
|
36 |
Dai MS, Chao TC (趙大中), Chiu CF, Lu YS, Shiah HS, Jackson C, Hung N, Zhi J, Cutler DL, Kwan R, Kramer D, Chan WK, Qin A, Tseng KC, Hung CT, Chao TY. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study |
|
37 |
Tseng CW, Teng HW (鄧豪偉), Lin CC, Lei HJ, Hung JJ, Liang WY, Hsia CY, Chou SC, Lin HH, Huang SC, Cheng HH, Lan YT, Wang HS, Yang SH, Chen WS, Lin JK, Jiang JK, Chang SC, Chau GY. Surgical strategy for colorectal cancer with synchronous liver and extrahepatic metastases: A scoring system and2023 Decision tree model |
|
38 |
Tseng LM, Lau KY, Chen JL, Chu PY, Huang TT, Lee CH, Wang WL, Chang YY, Huang CT, Huang CC, Chao TC (趙大中), Tsai YF, Lai JI (賴峻毅), Dai MS, Liu CY* (劉峻宇). Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model |
|
39 |
Yen CC (顏厥全), Yang YH, Ku HY, Hu HM, Lo SS, Chang HC, Chao Y (趙毅), Chen JS, Wang HP, Wang TE, Bai LY, Wu MS, Yen CJ, Chen LT, Shan YS. The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal2023 Junction cancer: A population-based cohort study |
|
40 |
Chang CH, Peng WY, Lee WH, Lin TY, Yang MH (楊慕華), Dalley JW, Tsai TH. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier |
|
41 |
Chang YW, Hsiao HW, Chen JP, Tzeng SF, Tsai CH, Wu CY, Hsieh HH, Carmona SJ, Andreatta M, Di Conza G, Su MT, Koni PA, Ho PC, Chen HK, Yang MH* (楊慕華). A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8(+) T cells |
|
42 |
Chao TC (趙大中), Tsai YF, Liu CY (劉峻宇), Lien PJ, Lin YS, Feng CJ, Chen YJ, Lai JI (賴峻毅), Hsu CY, Lynn JJ, Huang CC, Tseng LM. Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis |
|
43 |
Chang CH, Peng WY, Lee WH, Lin TY, Yang MH (楊慕華), Dalley JW, Tsai TH. . Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101 |
|
44 |
Chen CW (陳智文), Ou TS, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang YW, Lin YZ, Chao Y (趙毅), Wang LW, Teng HW (鄧豪偉). Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability |
|
45 |
Wu YH, Chao HS, Chiang CL, Luo YH, Chiu CH, Yen SH, Liu CY (劉峻宇), Chiou JF, Burnouf T, Chen YJ, Wang PY, Chao TY, Hsu SM, Lu LS. Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell-derived organoids |
|
46 |
Liu CY* (劉峻宇). Understanding Gastric Adenosquamous Cell Carcinoma: Insights from Immunoprofiling |
|
47 |
Wang YH, Wu WC (吳紋綺), Hsiao LT, Ma SH, Chen CC, Ho YH. Acquired hemophilia A in a Taiwanese patient with bullous pemphigoid |
|
48 |
Huang CC, Tsai YF, Liu CY (劉峻宇), Lien PJ, Lin YS, Chao TC (趙大中), Feng CJ, Chen YJ, Lai JI (賴峻毅), Cheng HF, Chen BF, Hsu CY, Chiu JH, Tseng LM. Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer |
|
49 |
Wu CE, Liao YH, Wu CL, Yen RF, Lin CC, Yang MH (楊慕華), Yen CC (顏厥全), Su WC, Yen CJ, Chang YF, Wu MF, Yang Y, Lin CY, Yang WC, Wang HC, Li CY, Ho YY, Chang YY, Wu CS, Hsu HC, Chen KH, Huang Y, Chen CJ, Chuang PJ, Lai YC, Huang YY, Tseng NC, Huang YT, Chu CY, Wen-Cheng Chang J. Clinical practice consensus for the diagnosis and management of melanoma in Taiwan |
|
50 |
Chen ZR, Chueh CH, Chiang NJ* (姜乃榕), Tsai YW. Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration |
|
51 |
Chang CH, Cheng TY, Yeh WW, Luo YL, Campbell M, Kuo TC, Shen TW, Hong YC, Tsai CH, Peng YC, Pan CC, Yang MH (楊慕華), Shih JC, Kung HJ, Huang WJ, Chang PC, Lin TP. REST-repressed lncRNA LINC01801 induces neuroendocrine d(IFferentiation in prostate cancer via transcriptional activation of autophagy |
|
52 |
Chiu JWY, Lee SC, Ho JC, Park YH, Chao TC (趙大中), Kim SB, Lim E, Lin CH, Loi S, Low SY, Teo LLS, Yeo W, Dent R. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pac(IFic Multidisciplinary Panel |
|
53 |
Chang CH, Peng WY, Lee WH, Yang L, Lin TY, Yang MH (楊慕華), Tsai TH. Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat |
|
54 |
Wang SF, Lin YS, Yeh WY, Chang YL, Chiang CE, Chen CH, Tseng LM, Lee HC, Liu CY* (劉峻宇), Cheng HM. The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis |
|
55 |
Hou MH, Lee CY, Ho CY, Yu TY, Hung GY, Huang FL, Chiou TJ, Liu CY (劉峻宇), Yen HJ. Donor Lymphocyte Infusion for Prophylaxis and Treatment of Relapse in Pediatric Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplant |
|
56 |
Liu MT, Liang SY, Chao TC (趙大中), Tseng LM, Rosenberg J. The Behavioral Adaptations and Barriers of Patients Employing Non-Pharmacological Strategies for Cancer Pain Management-A Qualitative Study |
|
57 |
Huang SC, Chang SC, Liao TT, Yang MH* (楊慕華). Detection and clinical signIFicance of CEACAM5 methylation in colorectal cancer patients |
|
58 |
Chan PW, Yu H, Hsu CH, Liu CY* (劉峻宇). Characteristics of early short-term traditional Chinese medicine in breast cancer patients: A population-based cohort study |
|
59 |
Lai JI (賴峻毅), Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY (劉峻宇), Tsai YF, Huang CC, Tseng LM, Hsu CC, Chao TC* (趙大中). Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients |
|
60 |
Liu MT, Liang SY, Chao TC (趙大中), Tseng LM, Rosenberg J. The Behavioral Adaptations and Barriers of Patients Employing Non-Pharmacological Strategies for Cancer Pain Management-A Qualitative Study |
|
61 |
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH (楊慕華), Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial |
|
62 |
Chang GC, Chiu CH, Yu CJ, Chang YC, Chang YH, Hsu KH, Wu YC, Chen CY, Hsu HH, Wu MT, Yang CT, Chong IW, Lin YC, Hsia TC, Lin MC, Su WC, Lin CB, Lee KY, Wei YF, Lan GY, Chan WP, Wang KL, Wu MH, Tsai HH, Chian CF, Lai RS, Shih JY, Wang CL, Hsu JS, Chen KC, Chen CK, Hsia JY, Peng CK, Tang EK, Hsu CL, Chou TY, Shen WC, Tsai YH, Tsai CM (蔡俊明), Chen YM, Lee YC, Chen HY, Yu SL, Chen CJ, Wan YL, Hsiung CA, Yang PC; TALENT Investigators. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study |
|
63 |
Tseng LM, Huang CC, Tsai YF, Chen JL, Chao TC (趙大中), Lai JI (賴峻毅), Lien PJ, Lin YS, Feng CJ, Chen YJ, Chiu JH, Hsu CY, Liu CY* (劉峻宇). Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers |
|
64 |
Chen TW, Dai MS, Tseng LM, Chen SC, Chao TY, Chao TC (趙大中), Chang YC, Chiu CF, Liu CT, Lin CH, Liu CY (劉峻宇), Chen YF, Chang DY, Yu JC, Rau KM, Hsieh YY, Shen SC, Huang SM, Cheng AL, Lu YS. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial |
|
65 |
Cheng HF, Tsai YF, Liu CY (劉峻宇), Hsu CY, Lien PJ, Lin YS, Chao TC (趙大中), Lai JI (賴峻毅), Feng CJ, Chen YJ, Chen BF, Chiu JH, Tseng LM, Huang CC. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study |
|
66 |
Chen BF, Tsai YF, Lien PJ, Lin YS, Feng CJ, Chen YJ, Cheng HF, Liu CY (劉峻宇), Chao TC (趙大中), Lai JI (賴峻毅), Tseng LM, Huang CC. Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan |
|
67 |
Ho IW (何奕緯), Pan YL, Lai JI (賴峻毅), Liu CY* (劉峻宇). Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience |
|
68 |
Su YY, Chiang NJ (姜乃榕), Chiu TJ, Huang CJ, Hsu SJ, Lin HC, Yang SH, Yang Y, Chou WC, Chen YY, Bai LY, Li CP, Chen JS. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation |
|
69 |
Tobias J, Högler S, Raigel M, Lin DS, Chao Y (趙毅), Kenner L, Garner-Spitzer E, Yavrom S, Ede NJ, Zielinski CC, Kundi M, Wiedermann U. Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion |
最後更新：